Sarcopenia-Pipeline Review, H2 2015

Sarcopenia-Pipeline Review, H2 2015

  • Products Id :- GMDHC6877IDB
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sarcopenia-Pipeline Review, H2 2015


Global Markets Direct's, 'Sarcopenia-Pipeline Review, H2 2015', provides an overview of the Sarcopenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Sarcopenia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Sarcopenia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Sarcopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Sarcopenia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Sarcopenia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sarcopenia Overview 7

Therapeutics Development 8

Pipeline Products for Sarcopenia-Overview 8

Pipeline Products for Sarcopenia-Comparative Analysis 9

Sarcopenia-Therapeutics under Development by Companies 10

Sarcopenia-Therapeutics under Investigation by Universities/Institutes 11

Sarcopenia-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Sarcopenia-Products under Development by Companies 14

Sarcopenia-Products under Investigation by Universities/Institutes 15

Sarcopenia-Companies Involved in Therapeutics Development 16

GlaxoSmithKline Plc 16

Myos Corporation 17

Neurotune AG 18

Novartis AG 19

PolyNovo Limited 20

PsiOxus Therapeutics Limited 21

Regeneron Pharmaceuticals, Inc. 22

Sumitomo Dainippon Pharma Co., Ltd. 23

Sarcopenia-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

AOD-9604-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ARM-210-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

bimagrumab-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

BIO-101-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

BIO-103-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Espindolol-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

NEP-28-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

NT-1654-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Proteins for Musculoskeletal Disorders-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Recombinant Protein for Sarcopenia-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

S-107-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

trevogrumab-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Sarcopenia-Recent Pipeline Updates 50

Sarcopenia-Dormant Projects 54

Sarcopenia-Discontinued Products 55

Sarcopenia-Product Development Milestones 56

Featured News & Press Releases 56

Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 56

Dec 14, 2011: Calzada Announces New Applications For AOD9604 56

Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 57

Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia 58

Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

Number of Products under Development for Sarcopenia, H2 2015 8

Number of Products under Development for Sarcopenia-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Products under Investigation by Universities/Institutes, H2 2015 15

Sarcopenia-Pipeline by GlaxoSmithKline Plc, H2 2015 16

Sarcopenia-Pipeline by Myos Corporation, H2 2015 17

Sarcopenia-Pipeline by Neurotune AG, H2 2015 18

Sarcopenia-Pipeline by Novartis AG, H2 2015 19

Sarcopenia-Pipeline by PolyNovo Limited, H2 2015 20

Sarcopenia-Pipeline by PsiOxus Therapeutics Limited, H2 2015 21

Sarcopenia-Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 22

Sarcopenia-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 23

Assessment by Monotherapy Products, H2 2015 24

Number of Products by Stage and Target, H2 2015 26

Number of Products by Stage and Mechanism of Action, H2 2015 28

Number of Products by Stage and Route of Administration, H2 2015 30

Number of Products by Stage and Molecule Type, H2 2015 32

Sarcopenia Therapeutics-Recent Pipeline Updates, H2 2015 50

Sarcopenia-Dormant Projects, H2 2015 54

Sarcopenia-Discontinued Products, H2 2015 55

List of Figures

Number of Products under Development for Sarcopenia, H2 2015 8

Number of Products under Development for Sarcopenia-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 24

Number of Products by Top 10 Targets, H2 2015 25

Number of Products by Stage and Top 10 Targets, H2 2015 25

Number of Products by Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Top 10 Routes of Administration, H2 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29

Number of Products by Top 10 Molecule Types, H2 2015 31

Number of Products by Stage and Top 10 Molecule Types, H2 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

GlaxoSmithKline Plc

Myos Corporation

Neurotune AG

Novartis AG

PolyNovo Limited

PsiOxus Therapeutics Limited

Regeneron Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Sarcopenia Therapeutic Products under Development, Key Players in Sarcopenia Therapeutics, Sarcopenia Pipeline Overview, Sarcopenia Pipeline, Sarcopenia Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]